MedTrace Logo

HLA Sensitization in Severely Burned Patients

NCT02537821 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-11-21

No results posted yet for this study

Summary

Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary allogeneic skin. Besides that, inflammatory markers, such as WBC (white blood cell count), CRP (C-reactive protein), PCT (Procalcitonin) and two novel biomarkers (PSP (pancreatic stone protein), ST2) are to be investigated in severely burned patients.

Conditions

  • Severely Burned Patients

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Jan Plock, M.D. · Raemistrasse 100, 8091

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537821 on ClinicalTrials.gov